MiR-17-5p/RRM2 regulated gemcitabine resistance in lung cancer A549 cells

The main objective of this study is to investigate the regulatory roles of the miR-17-5p/RRM2 axis in A549/G+ cells' gemcitabine resistance. The cell viability was determined using CCK8 and clonogenic assays. Gene expression level analysis by RT-qPCR and Western blotting. Cell cycle analysis by flow cytometry. The dual luciferase activity assay was used to verify the target gene of miR-17-5p. In gemcitabine-resistant cell line A549G+, the drug resistance decreased after up-regulation of MiR-17-5p expression. The proportion of cell cycle G1 phase increased, and the S phase decreased. The expression level of cell cycle-related proteins CCNE1, CCNA2, and P21 decreased. The opposite results emerged after the down-regulation of MiR-17-5p expression in gemcitabine-sensitive cell line A549G-. The expression levels of PTEN and PIK3 in A549G+ cells were higher than in A549G-cells, but p-PTEN was lower than that in A549G-. After up-regulating the expression of MiR-17-5p in A549G+, the expression levels of p-PTEN increased, and the expression level of p-AKT decreased. After down-regulating miR-17-5p expression, the opposite results emerged. The dual-luciferase reporter assay and restorative experiments proved that RRM2 is one of the target genes for MiR-17-5p. Our results suggested that the miR-17-5p/RRM2 axis could adjust gemcitabine resistance in A549 cells, and the p-PTEN/PI3K/AKT signal pathway might be involved in this regulatory mechanism.

Automated summary

The study aimed to investigate the regulatory roles of the miR-17-5p/RRM2 axis in gemcitabine resistance in A549/G+ cells. Cell viability was assessed using CCK8 and clonogenic assays. Gene expression levels were analyzed by RT-qPCR and Western blotting. Cell cycle analysis was performed using flow cytometry. The results showed that up-regulating miR-17-5p expression reduced drug resistance and altered cell cycle distribution in gemcitabine-resistant cells. Down-regulating miR-17-5p had the opposite effects in gemcitabine-sensitive cells. The miR-17-5p/RRM2 axis could potentially regulate gemcitabine resistance in A549 cells through the p-PTEN/PI3K/AKT signaling pathway.